West Nile Virus Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Dose-Escalation Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of MGAWN1, a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus, in Healthy Adults
The primary purpose of this phase 1, double-blind, cohort study is to evaluate the safety, tolerability, and pharmacokinetics of escalating doses of MGAWN1 administered as a single intravenous (IV) infusion to healthy adults. Subjects will be enrolled sequentially into one of 5 dose-level cohorts, with 8 subjects in each cohort. Six subjects in each cohort will receive MGAWN1 (a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus) and 2 will receive a saline control.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00069316 -
Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease
|
Phase 2 | |
| Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
| Completed |
NCT00138463 -
West Nile Virus Natural History
|
N/A | |
| Completed |
NCT00068055 -
IVIG - West Nile Encephalitis: Safety and Efficacy
|
Phase 1/Phase 2 | |
| Completed |
NCT00069303 -
Natural History of West Nile Virus Infection
|
N/A | |
| Withdrawn |
NCT04371003 -
Prospective Investigation of Oxidative Stress in West Nile Virus Infection
|
||
| Completed |
NCT00387283 -
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
|
Phase 1 | |
| Completed |
NCT05294003 -
West Nile Virus Seroprevalence Under Bird Ringers
|
||
| Completed |
NCT02186626 -
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
|
Phase 1 |